The Increasing Prevalence of Diabetes and Kidney Stones is expected to Boost the Growth of the Global Urinary Tract Infections Market at a CAGR of 3.50% during the forecast period of 2023 to 2032

Pune, India, January 2021, MRFR Press Release/- Market Research Future has published a Cooked Research Report on the Global Urinary Tract Infections Market.

Market Highlights

Global Urinary Tract Infections Market is expected to register a CAGR of 3.50% during the forecast period and is expected to hit USD 12.21 billion by 2032.

A urinary tract infection (UTI) is an infection in any part of the urinary system such as kidneys, ureters, bladder, and urethra. UTIs can be caused for a variety of causes, including unsafe sex, lack of hygiene, and diabetes. UTIs are more common in women than men due to inherent complications in the female reproductive system. According to the World Health Organization, 1 million hospitalizations of women occur each year due to UTIs, which affects almost half of the female population around the world.

The growth of the global urinary tract infections market is attributed to the increasing prevalence of diabetes and kidney stones. The launch of combination drugs is also resulting in market growth. The rise in research & development (R&D) of a novel class of antibiotics for UTIs is also expected to aid in the growth of the market. For instance, in August 2020, researchers at the California Polytechnic State University reported the development of a new class of antibiotics for UTIs, which targets bacterial iron uptake, at the American Chemical Society (ACS) Fall 2020 Virtual Meeting & Expo. Moreover, in July 2019, The US Food and Drug Administration has approved Merck & Co., Inc.’s Recarbrio (imipenem, cilastatin, and relebactam), an antibacterial drug to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Segment Analysis

Global Urinary Tract Infections Market has been divided based on drug class, application, pathogen, and end user. The market, based on drug class, has been segmented into quinolones, β-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The quinolones are further sub-segmented into ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is divided into avycaz, cedax, cefdinir, and cefditoren. β-lactam is further segmented into amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil.

The market, based on application, has been bifurcated into urethritis, cystitis, and pyelonephritis. The market, based on pathogen, has been bifurcated into Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. On the basis of end-user, the global urinary tract infections market has been classified as hospitals, clinics, self-administered, and others.

Regional Analysis

The global UTI market, on the basis of region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. In 2019, the Americas accounted for the largest share of the global market. This large share is majorly attributed to the presence of key manufacturers, the rising prevalence of UTIs, and the growing aging woman population in the region. Europe is the second-largest regional market in terms of revenue. Urinary disorders account for a tremendous economic burden in Europe. The high-income countries, the EU5 (France, Germany, Italy, Spain, and the UK), typically spend 2–3% of their annual health budget on the treatment of urinary disease as per a bulletin published by the WHO.

Asia-Pacific is expected to be the fastest-growing market for UTI during the forecast period. This can be attributed to the developing economies and highly populated countries such as China, India, and South Korea. The African market is growing and will continue to grow at a steady pace. The rapid urbanization in these countries has led to increased exposure to numerous environmental toxins, a highly infectious disease burden, and rising incidences of non-communicable diseases.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Urinary Tract Infection Market Research Report

Key Players

MRFR recognizes the following companies as the Key Players in the Global Urinary Tract Infections Market— Pfizer Inc, Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc, Eli Lily and Company, Allergan, Cipla Inc, Teva Pharmaceuticals, GlaxoSmithKline Plc, and Bayer AG.

Key Findings of the Study

• Global Urinary Tract Infections Market was valued at USD 12,513.1 million and is expected to register a CAGR of 3.62% during the assessment period.


• The Americas accounted for the largest share of the global market, majorly attributed to the presence of major manufacturers, rising prevalence of urinary tract infection, and the growing aging woman population in the region.


• Based on drug class, the quinolones segment accounted for the largest market share of 41.57% in 2019.


• Based on application, the urethritis segment dominated the market with a value share of 40.79% in 2019.


• Based on the pathogen, the Escherichia coli segment accounted for the largest market share of 65.59% in 2019, with a market value of USD 6,225.31 million.


• Based on end-user, the hospital segment dominated the market with a value share of 42.19% in 2019.